AU2002231777A1 - Use of mglur5 antagonists for the treatment of pruritic conditions - Google Patents

Use of mglur5 antagonists for the treatment of pruritic conditions

Info

Publication number
AU2002231777A1
AU2002231777A1 AU2002231777A AU2002231777A AU2002231777A1 AU 2002231777 A1 AU2002231777 A1 AU 2002231777A1 AU 2002231777 A AU2002231777 A AU 2002231777A AU 2002231777 A AU2002231777 A AU 2002231777A AU 2002231777 A1 AU2002231777 A1 AU 2002231777A1
Authority
AU
Australia
Prior art keywords
treatment
mglur5 antagonists
pruritic conditions
conditions
mglur5
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002231777A
Other languages
English (en)
Inventor
Fabrizio Gasparini
Josef Gottfried Meingassner
Laszlo Urban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Original Assignee
Novartis Pharma GmbH Austria
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria filed Critical Novartis Pharma GmbH Austria
Publication of AU2002231777A1 publication Critical patent/AU2002231777A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2002231777A 2001-02-07 2002-02-06 Use of mglur5 antagonists for the treatment of pruritic conditions Abandoned AU2002231777A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0103045.1 2001-02-07
GBGB0103045.1A GB0103045D0 (en) 2001-02-07 2001-02-07 Organic Compounds
PCT/EP2002/001250 WO2002062323A2 (en) 2001-02-07 2002-02-06 Use of mglur5 antagonists for the treatment of pruritic conditions

Publications (1)

Publication Number Publication Date
AU2002231777A1 true AU2002231777A1 (en) 2002-08-19

Family

ID=9908300

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002231777A Abandoned AU2002231777A1 (en) 2001-02-07 2002-02-06 Use of mglur5 antagonists for the treatment of pruritic conditions

Country Status (13)

Country Link
US (2) US20040106582A1 (enExample)
EP (1) EP1359905B1 (enExample)
JP (2) JP2004517947A (enExample)
CN (1) CN1253151C (enExample)
AT (1) ATE333869T1 (enExample)
AU (1) AU2002231777A1 (enExample)
BR (1) BR0206917A (enExample)
CA (1) CA2433409C (enExample)
DE (1) DE60213365T2 (enExample)
ES (1) ES2271229T3 (enExample)
GB (1) GB0103045D0 (enExample)
PT (1) PT1359905E (enExample)
WO (1) WO2002062323A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
GB0322612D0 (en) * 2003-09-26 2003-10-29 Novartis Ag Organic compounds
EP1677790A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes ii
EP1677789A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes i
EP1677788A1 (en) * 2003-10-31 2006-07-12 AstraZeneca AB Alkynes iii
GB0503646D0 (en) * 2005-02-22 2005-03-30 Novartis Ag Organic compounds
GB0508319D0 (en) 2005-04-25 2005-06-01 Novartis Ag Organic compounds
CA2881638A1 (en) 2012-08-30 2014-03-06 Nippon Shinyaku Co., Ltd. Pyridine derivative and medicine
JP6603334B2 (ja) * 2015-06-03 2019-11-06 エフ．ホフマン−ラ ロシュ アーゲー エチニル誘導体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
FR2719044B1 (fr) * 1994-04-26 1996-05-31 Cird Galderma Nouveaux composés bi-aromatiques acétylénés à groupement adamantyle, compositions pharmaceutiques et cosmétiques les contenant et utilisations.
US5498795A (en) * 1994-12-29 1996-03-12 Allergan, Inc. Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
US5534641A (en) * 1994-12-29 1996-07-09 Allergan Acetylenes disubstituted with 2-tetrahydropyranoxyaryl and aryl or heteroaryl groups having retinoid-like biological activity
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6774138B2 (en) * 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds

Also Published As

Publication number Publication date
CN1253151C (zh) 2006-04-26
ATE333869T1 (de) 2006-08-15
DE60213365D1 (de) 2006-09-07
PT1359905E (pt) 2006-11-30
JP2004517947A (ja) 2004-06-17
CA2433409C (en) 2010-04-20
CN1535143A (zh) 2004-10-06
DE60213365T2 (de) 2007-08-09
WO2002062323A3 (en) 2003-03-20
BR0206917A (pt) 2004-02-03
US20040106582A1 (en) 2004-06-03
EP1359905B1 (en) 2006-07-26
CA2433409A1 (en) 2002-08-15
EP1359905A2 (en) 2003-11-12
ES2271229T3 (es) 2007-04-16
GB0103045D0 (en) 2001-03-21
JP2012131829A (ja) 2012-07-12
WO2002062323A2 (en) 2002-08-15
US20070265279A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
WO2003073999A3 (en) Pini-modulating compounds and methods of use thereof
WO2003074550A3 (en) Pin1-modulating compounds and methods of use thereof
AU2002341920A1 (en) Chemical compounds
MXPA04002931A (es) Heterociclos que contienen nitrogeno de 5 miembros sustituidos con fenilo para el tratamiento de la obesidad.
AU2002213336A1 (en) Substituted heterocyclic compounds for treating multidrug resistance
MXPA03011197A (es) Benzoilsufonamidas y sulfonilbenzamidinas que se usan como agentes antitumorales.
SG149063A1 (en) Use of modified cyclosporins for the treatment of hcv disorders
WO2004047760A3 (en) Novel chemical compounds
AU3831301A (en) Method for treating ocular pain
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
AU2001272852A1 (en) Composition for the treatment of migraine
AU2002338807A1 (en) Use of c-kit inhibitors for the treatment of myeloma
AU2002358390A1 (en) Novel compounds
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA04007391A (es) Heterociclos triciclicos fusionados utiles para el tratamiento de padecimientos hiper-proliferantes.
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
AU2003290592A1 (en) Antitumor benzoylsulfonamides
WO2005007123A3 (en) Pin1-modulating compounds and methods of use thereof
MXPA04003755A (es) Endoprotesis vasculares.
IL152097A0 (en) Use of pyrazole derivatives for treating infertility
AU2002231777A1 (en) Use of mglur5 antagonists for the treatment of pruritic conditions
WO2002076396A3 (en) Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
MXPA04000272A (es) Derivados de 4-aminociclohexanol sustituidos.
EP1436279B8 (en) Chemical compounds
EP1469844A4 (en) METHOD AND CONNECTION FOR THE PROPHYLAXIS OR TREATMENT OF IMMUNE WEAKNESS, SUCH AS AIDS

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase